<DOC>
	<DOCNO>NCT00648167</DOCNO>
	<brief_summary>This study evaluate safety tolerability Zerenex™ ( ferric citrate ) treatment hyperphosphatemia patient End-Stage Renal Disease .</brief_summary>
	<brief_title>A Safety Tolerability Study Zerenex ( Ferric Citrate ) Patients With End-Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description>The purpose study evaluate safety tolerability Zerenex™ ( ferric citrate ) treatment hyperphosphatemia patient End-Stage Renal Disease . These patient switch Zerenex™ current high dose phosphate binder , base serum phosphorus level , titrate 3.4g/day Zerenex™ maximum tolerate safe dos Zerenex™ . Doses adjust weekly , base serum phosphorus level , maximum dose administer approximately 12g/day .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Males nonpregnant , nonlactating female Age &gt; 18 year On thrice weekly hemodialysis least previous 3 month prior randomization Phosphorous level ≥3.5mg/dL Screening Visit On least 12 tablets/capsules/day calcium acetate ( 667mg ) , calcium carbonate ( 500mg ) , lanthanum carbonate ( 500mg ) , sevelamer hydrochloride ( 800mg two 400mg tablet ) , combination agent Serum ferritin &lt; 1000micrograms/L Transferrin Saturation ( TSAT ) &lt; 50 % Willing discontinue current phosphate binder ( ) initiate Zerenex Willing able give inform consent Parathyroidectomy within 6 month prior Screening Actively symptomatic GI disease peptic ulcer disease , gastro esophageal reflux , diverticulosis , irritable bowel syndrome ( treat asymptomatic permit ) History document inflammatory bowel disease erosive esophagitis Serum Phosphorus level &gt; 10.0 mg/dL document 3 monthly laboratory ( do routinely dialysis unit ) 3 month prior Screening Visit History multiple drug allergy History malignancy last 5 year ( treated cervical skin cancer may permit approve CCC ) Previous intolerance oral ferric citrate Absolute requirement oral iron therapy Absolute requirement Vitamin C ( multivitamin [ Neprocaps , Renaphro , etc . ] allow ) Absolute requirement calcium , magnesium , aluminum contain drug meal Psychiatric disorder interfere patient 's ability comply study protocol Inability tolerate oral drug intake Planned surgery hospitalization study ( schedule outpatient access surgery allow ) Any medical condition render patient unable unlikely complete study would interfere optimal participation study produce significant risk patient Receipt investigational drug within 30 day randomization Inability cooperate study personnel history noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ESRD</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>dialysis</keyword>
	<keyword>kidney failure</keyword>
	<keyword>renal failure</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>phosphate binder</keyword>
	<keyword>phosphorus</keyword>
</DOC>